RxDoctor Payments Data

Owais Malick, MD

Advanced Heart Failure and Transplant Cardiology · Downers Grove, ILNPI 1326337130

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $61,430 of the $77,777 with a category attached, or 79.0%. Actelion Pharmaceuticals US, Inc. accounts for 82.0% of it on its own, with 18 other manufacturers making up the rest.

$77,777in general payments, 2019–2025

Across 194 payments — averaging $400.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Actelion Pharmaceuticals US, Inc.$64K
  • Pfizer$7K
  • Abiomed$3K
  • Abbott$2K
  • Cvrx, Inc.$307
  • Ancora Heart, Inc.$299
  • plus $996 from 13 others

What the payments were for

  • Consulting fees$3,0244%
  • Speaking & faculty fees$61,43079%
  • Travel & lodging$6,4458%
  • Food & beverage$6,8789%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$77,777 in reported general payments places this provider in the 80th percentile of 56 advanced heart failure and transplant cardiology providers in Illinois.

See all advanced heart failure and transplant cardiology providers in Illinois

Medicare billing

Part B allowed, 2024
$205,156
Medicare patients
860
Services billed
2,239

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis71$1,772,103
OpsumitMacitentan42$531,629
EntrestoSacubitril/Valsartan415$516,407
JardianceEmpagliflozin402$399,891
Tyvaso DpiTreprostinil13$298,531
AdempasRiociguat11$156,514
EliquisApixaban120$140,097
FarxigaDapagliflozin Propanediol146$138,938
CamzyosMavacamten12$105,239
XareltoRivaroxaban54$64,322
Ambrisentan12$19,234
BrilintaTicagrelor24$17,120
Torsemide440$10,745
CorlanorIvabradine Hcl12$10,406
Sildenafil Citrate40$7,545

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax, Eliquis$7,467$1,912,200191 claims
Actelion Pharmaceuticals US, Inc.Opsumit$63,748$531,62942 claims
NovartisEntresto$61$516,407415 claims
Boehringer IngelheimJardiance$59$399,891402 claims
AstraZenecaFarxiga, Brilinta$21$156,057170 claims
Johnson & JohnsonXarelto$31$64,32254 claims
AmgenCorlanor$25$10,40612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 56 advanced heart failure and transplant cardiology providers in Illinois.

Other advanced heart failure and transplant cardiology in Downers Grove

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →